Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
63 hedge funds and large institutions have $109M invested in Regulus Therapeutics in 2024 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 10 closing their positions.
180% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 10
176% more call options, than puts
Call options by funds: $329K | Put options by funds: $119K
40% more funds holding
Funds holding: 45 → 63 (+18)
14.11% more ownership
Funds ownership: 79.56% → 93.68% (+14%)
7% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 14
26% less capital invested
Capital invested by funds: $147M → $109M (-$37.8M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$9.9M |
| 2 |
BlackRock
New York
|
+$9.05M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.68M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.03M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.5M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.9M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$2.33M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.09M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$1.54M |
RGLS Hedge Fund Activity: Q2 2024 in Review
63 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q2 2024, worth a combined $109M — down 26% from $147M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new RGLS positions and 10 closed out — a net gain of 18 holders — while 13 added to existing stakes and 14 trimmed.
The largest buyer was Octagon Capital Advisors, opening a new position worth an estimated $9.9M. The largest seller was Soleus Capital Management, exiting entirely with an estimated $4.5M sold.
- 63 institutional investors held Regulus Therapeutics (RGLS) as of Q2 2024, up from 45 in Q1 2024.
- Funds reported $109M of Regulus Therapeutics stock for Q2 2024, down 26% quarter-over-quarter.
- 28 funds opened new Regulus Therapeutics positions in Q2 2024 and 10 closed out, a net change of +18 holders.
- The largest Regulus Therapeutics buyer in Q2 2024 was Octagon Capital Advisors, an estimated $9.9M added.
- The largest Regulus Therapeutics seller in Q2 2024 was Soleus Capital Management, an estimated $4.5M sold.
Based on aggregated 13F filings for Q2 2024.